Capricor Therapeutics : Expands Commercial Leadership Team

About this update from Capricor Therapeutics, Inc.

May 28, 2026 Capricor Therapeutics Expands Commercial Leadership Team --Michael Maurer joins as Chief Commercial Officer, further strengthening Capricor's launch readiness efforts for Deramiocel in Duchenne muscular dystrophy-- SAN DIEGO, May 28, 2026 -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Maurer as Chief Commercial Officer, effective immediately. With two decades of experience across rare disease commercialization, patient access, and launch strategy, Mr. Maurer will bolster the Company's existing commercial leadership team as it advances preparations for the potential launch of Deramiocel, Capricor's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). Complementing the Company's current commercial capabilities, Mr. Maurer will bring deep expertise across specialty pharmacy and distribution, reimbursement strategy, patient support services, and launch execution for complex biologic therapies. Through roles at Amicus Therapeutics (now part of BioMarin), Sarepta Therapeutics, and Bristol Myers Squibb, Mr. Maurer has led commercial and patient-focused initiatives for specialty medicines across neuromuscular disorders, neuroscience, and immunology. At Sarepta, he was responsible for the U.S. launch of ELEVIDYS, an FDA-approved gene therapy for DMD, and oversaw the commercial strategy for the company's approved RNA therapies. "Michael's experience supporting the Duchenne community and helping bring complex rare disease therapies to patients makes him an exceptional addition to Capricor's leadership team," said Linda Marbán, Ph.D., CEO of Capricor. "We have made strategic investments in our commercial readiness capabilities and assembled a highly experienced team to support a thoughtful and sustainable launch strategy for Deramiocel. Michael's leadership further strengthens our ability to prepare for commercialization while keeping DMD patients and families at the center of everything we do." In his role at Capricor, Mr. Maurer will oversee the Company's global commercial organization and launch readiness efforts, including market access, patient support, distribution strategy, and operational planning. Together with his team, he will work to ensure a coordinated and patient-cente...

View stock analysis, news, and events for Capricor Therapeutics, Inc.